@ARTICLE{
author={Brodowicz Thomas,Ciuleanu Tudor E,Radosavljevic Davorin Z,Shacham-Shmueli Einat,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank M,Purkalne Gunta,Messinger D,Zielinski Christoph},
year={2013},
title={FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study},
journal={ANNALS OF ONCOLOGY},
volume={24},
number={7},
pages={1769-1777},
document_type={Article},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shmueli E,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank M,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={29},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shmueli E,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank Magdolna,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={29},
number={4},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shacham-Shmueli Einat,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Kahan Zsuzsanna,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab Weekly (Q1W) Versus Every Two Weeks (Q2W) Plus Folfox4 as First-line Therapy in Patients (PTS) with Kras Wild-Type (WT) Metastatic Colorectal Cancer (MCRC)},
journal={ANNALS OF ONCOLOGY},
volume={22},
number={},
pages={v22-v22},
document_type={Meeting Abstract},
}